Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 9/20 | 0.50 |
| ▸ | RAF1 | P04049 | 8/20 | 0.50 |
| ▸ | USP36 | Q9P275 | 7/20 | 0.49 |
| ▸ | CSF1R | P07333 | 2/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29536884 | 0.85 | BRAF (0.58) | BRAFRAF1CSF1RABL1LCK | |
| SCHEMBL2887561 | 0.85 | BRAF (0.58) | BRAFRAF1CSF1RABL1LCK | |
| SCHEMBL25421949 | 0.84 | SLC6A3 (0.43) | BRAF | |
| SCHEMBL28630762 | 0.83 | RAF1 (0.49) | BRAFRAF1 | |
| SCHEMBL31312305 | 0.83 | RAF1 (0.49) | BRAFRAF1 | |
| SCHEMBL16035424 | 0.82 | RAF1 (0.54) | BRAFRAF1 | |
| SCHEMBL29427236 | 0.82 | RAF1 (0.54) | BRAFRAF1 | |
| SCHEMBL29536338 | 0.80 | RAF1 (0.52) | BRAFRAF1MAPK14 | |
| SCHEMBL25421239 | 0.80 | RAF1 (0.52) | BRAFRAF1MAPK14 | |
| SCHEMBL25984083 | 0.80 | RAF1 (0.54) | BRAFRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108699065-B | Tricyclic compounds and compositions as kinase inhibitors | 诺华股份有限公司 | 2021-08-31 | — | — | CN | disclosed |
| EP-3390404-B1 | TRICYCLIC COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2021-07-21 | — | — | EP | disclosed |
| EP-3390404-B1 | TRICYCLIC COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2021-07-21 | — | — | EP | disclosed |
| US-10377770-B2 | Tricyclic compounds and compositions as kinase inhibitors | NOVARTIS AG (CH) | 2019-08-13 | — | — | US | disclosed |
| US-10377770-B2 | Tricyclic compounds and compositions as kinase inhibitors | NOVARTIS AG (CH) | 2019-08-13 | — | — | US | disclosed |
| US-20180362542-A1 | TRICYCLIC COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-12-20 | — | — | US | disclosed |
| EP-3390404-A1 | TRICYCLIC COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | Novartis AG (CH) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017103824-A1 | TRICYCLIC COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017103824-A1 | TRICYCLIC COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180362542-A1 | TRICYCLIC COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | BRAF, RAF1, MAP3K1 | BRAF 1/4885RAF1 2/4885USP36 3324/4885 |
| US-10377770-B2 | Tricyclic compounds and compositions as kinase inhibitors | BRAF, RAF1, MAP3K1 | BRAF 1/4885RAF1 2/4885USP36 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.